- Home
- SEVN vs GLSI Comparison
SEVN vs GLSI Comparison
Compare SEVN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- GLSI
- Stock Information
- Founded
- SEVN 1986
- GLSI 2006
- Country
- SEVN United States
- GLSI United States
- Employees
- SEVN N/A
- GLSI N/A
- Industry
- SEVN Real Estate Investment Trusts
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- GLSI Health Care
- Exchange
- SEVN Nasdaq
- GLSI Nasdaq
- Market Cap
- SEVN 156.9M
- GLSI 134.6M
- IPO Year
- SEVN N/A
- GLSI 2020
- Fundamental
- Price
- SEVN $10.50
- GLSI $12.17
- Analyst Decision
- SEVN Strong Buy
- GLSI Strong Buy
- Analyst Count
- SEVN 2
- GLSI 1
- Target Price
- SEVN $13.50
- GLSI $39.00
- AVG Volume (30 Days)
- SEVN 78.3K
- GLSI 54.6K
- Earning Date
- SEVN 07-28-2025
- GLSI 08-26-2025
- Dividend Yield
- SEVN 10.67%
- GLSI N/A
- EPS Growth
- SEVN N/A
- GLSI N/A
- EPS
- SEVN 1.04
- GLSI N/A
- Revenue
- SEVN $29,272,000.00
- GLSI N/A
- Revenue This Year
- SEVN $7.45
- GLSI N/A
- Revenue Next Year
- SEVN $1.12
- GLSI N/A
- P/E Ratio
- SEVN $10.08
- GLSI N/A
- Revenue Growth
- SEVN N/A
- GLSI N/A
- 52 Week Low
- SEVN $10.01
- GLSI $8.06
- 52 Week High
- SEVN $14.66
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- SEVN 42.65
- GLSI 58.31
- Support Level
- SEVN $10.20
- GLSI $11.70
- Resistance Level
- SEVN $10.95
- GLSI $12.70
- Average True Range (ATR)
- SEVN 0.24
- GLSI 0.69
- MACD
- SEVN 0.08
- GLSI -0.01
- Stochastic Oscillator
- SEVN 52.13
- GLSI 67.28
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.